Lee's Pharmaceutical Holdings Limited (HKG:0950)

Hong Kong · Delayed Price · Currency is HKD

1.375

+0.255 (22.77%)

Aug 27, 2026, 3:44 PM HKT

-31.25% (1Y)

Market Cap	659.50M -44.6%
Revenue (ttm)	1.44B +2.6%
Net Income	91.94M -1.2%
EPS	0.16 -1.3%
Shares Out	588.84M
PE Ratio	7.17
Forward PE	n/a
Dividend	0.05 (3.88%)
Ex-Dividend Date	May 27, 2026

Volume	9,073,000
Open	1.235
Previous Close	1.120
Day's Range	1.235 - 1.425
52-Week Range	0.990 - 2.700
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About HKG:0950

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to trea... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1994

Employees 1,094

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 0950

Full Company Profile

Financial Performance

In 2025, HKG:0950's revenue was 1.44 billion, an increase of 2.57% compared to the previous year's 1.40 billion. Earnings were 91.94 million, a decrease of -1.25%.

Financial Statements